Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Interferon May Be Harmful in Retreatment of Hepatitis C

When patients with hepatitis C and chronic liver disease suffer relapses or fail to respond to initial treatment, monotherapy with interferon may not be a good idea, according to results from a recent meta-analysis. In fact, employing that approach may raise the risks for death and adverse effects.

Published
31 January 2013
From
Medscape (requires registration)
Vertex hepatitis C drug revenues plummet

Vertex Pharmaceuticals (Nasdaq: VRTX) saw sales of its hepatitis C drug, Incivek, drop off precipitously in the fourth quarter, year over year. The fast decline in Incivek sales, less than two years after its U.S. Food and Drug Administration approval.

Published
30 January 2013
From
Boston Business Journal (blog)
Infographic: Doctor-patient interactions about hepatitis C

Who does the talking when patients with hepatitis C visit the doctor? What do they discuss? On average, doctors talk more than twice as much (61 percent) as patients (29 percent) and six times more than caregivers (10 percent).

Published
30 January 2013
From
Health Care Communication News
Judge: Agency Could Have Stopped Exeter Hepatitis C Outbreak

A judge said a medical staffing agency could have stopped a hepatitis C outbreak that infected 32 Exeter Hospital patients.

Published
30 January 2013
From
Patch.com
Spanish research shows that liver stiffness can predict outcomes in people co-infected with HIV and hepatitis C

Liver stiffness is a strong predictor of hepatic complications and all-cause mortality in people co-infected with HIV and hepatitis C virus (HCV), Spanish investigators report in the

Published
30 January 2013
By
Michael Carter
Hepatitis C progress in pipeline: New drugs to treat virus expected be available in 2014-15

For more on this rapidly changing landscape, we turned to Dr. Donald M. Jensen, director of the Center for Liver Diseases at University of Chicago Medicine and a noted hepatitis C researcher, with more than 100 peer-reviewed articles.

Published
29 January 2013
From
Chicago Tribune
Phase II all-oral combination studies of simeprevir, TMC647055 and IDX719 for the treatment of hepatitis C to be initiated shortly

The collaboration will evaluate combinations including simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, TMC647055, a potent once daily NNI (non-nucleoside inhibitor) of the HCV polymerase, boosted with low dose ritonavir, being developed by Janssen and IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor.

Published
29 January 2013
From
Medivir press release
The Age-Old Debate of Whether to Biopsy in HCV: My Answer for 2013

Mark Sulkowski MD discusses the role of liver biopsy in the management of the HCV patient.

Published
25 January 2013
From
Clinical Care Options (requires registration)
Hepatitis C linked to ink

Researchers are hoping that people will do some research about where to get a tattoo, after a study found a link between body art and hepatitis C.

Published
25 January 2013
From
Reuters
Support Inclusion of Pegylated Interferon in the World Health Organization’s Essential Medicines List

Civil-society groups have an important but limited opportunity to advocate for the inclusion of pegylated interferon on the World Health Organization Essential Medicines List. Deadline Mid-February!

Published
23 January 2013
From
Treatment Action Group

Filter by country